Drug Approvals, Study Results, and Clinical Collaborations for Top-Line Growth - Research Report on Pfizer, Merck & Co., Cubist, AstraZeneca and Impax

Editor Note: For more information about this release, please scroll to bottom.

NEW YORK, July 23, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Pfizer Inc. (NYSE: PFE), Merck & Co. Inc. (NYSE: MRK), Cubist Pharmaceuticals Inc. (NASDAQ: CBST), AstraZeneca PLC (NYSE: AZN) and Impax Laboratories Inc. (NASDAQ: IPXL). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Pfizer Inc. Research Report

On July 15, 2013, Pfizer Inc. (Pfizer) announced that tofacitinib has been approved for the treatment of rheumatoid arthritis (RA) in patients who had an inadequate response to existing therapies in several additional countries including Switzerland, Argentina, Kuwait and UAE. Pfizer stated that Swissmedic, the Swiss agency for therapeutic products, approved tofacitinib as monotherapy or in combination with a disease modifying non-biologic antirheumatic agent, including methotrexate (MTX), in adult patients with moderate-to-severe active RA, who have had an inadequate response or intolerance to MTX. "More than 23 million people worldwide are living with rheumatoid arthritis and there remains an unmet need for additional treatments, with up to one-third of RA patients not adequately responding and about half who stop responding to any particular DMARD within five years," said Geno Germano, President and General Manager, Specialty Care and Oncology, Pfizer. "XELJANZ has a novel mechanism of action for the treatment of moderate-to-severe RA. With these approvals, we believe XELJANZ has the potential to change the way rheumatologists treat this chronic, and potentially disabling, disease, and we are proud to offer patients and physicians an additional treatment option." The Full Research Report on Pfizer Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/d702_PFE]

Merck & Co. Inc. Research Report

On July 14, 2013, Merck & Co. inc. (Merck) announced results from a Phase Ib study in patients with mild to moderate Alzheimer's disease (AD). In the study, β amyloid levels were analyzed as a measure of BACE (β-site amyloid precursor protein cleaving enzyme) activity. The study showed a dose-dependent decrease in β amyloid levels in cerebral spinal fluid (CSF) following administration of MK-8931, Merck's investigational oral β-site amyloid precursor protein cleaving enzyme (BACE1 or β secretase) inhibitor. "The amyloid β reduction observed with MK-8931 may offer an opportunity to further understand the role BACE1 inhibition plays in the underlying pathology of Alzheimer's disease," said Darryle Schoepp, Ph.D., Vice President of Neuroscience Early Development and Discovery Sciences, Merck. "Further evaluation of MK-8931 continues in our EPOCH study, a Phase II/III trial in patients with mild to moderate Alzheimer's." The Full Research Report on Merck & Co. Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/430d_MRK]

Cubist Pharmaceuticals Inc. Research Report

On July 18, 2013, Cubist Pharmaceuticals Inc. (Cubist) announced its Q2 2013 financial results. The Company reported total net revenues of $258.8 million, an increase of 12.2% YoY. Its non-GAAP adjusted operating income was $51.3 million compared to $71.1 million in Q2 2012. Non-GAAP diluted EPS was $0.42 compared to $0.56 in the Q2 2012. "We made important progress across the company this quarter, highlighted by continued strong top-line growth and advancement of our exciting late-stage pipeline," said Michael Bonney, Chief Executive Officer of Cubist. "We are pleased to have now secured Fast-Track status from the FDA for ceftolozane/tazobactam in all three of its potential indications, and we look forward to reporting top-line Phase 3 data from the cUTI and cIAI trials later this year. We are making progress against our Building Blocks of Growth goals and continue to enhance our leadership in the acute care environment." The Full Research Report on Cubist Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/92f2_CBST]

AstraZeneca PLC Research Report

On July 9, 2013, AstraZeneca Plc. (AstraZeneca) announced that it has signed an agreement with the University of Cambridge and Cancer Research UK for a two-year collaboration on three pre-clinical and clinical oncology projects. The collaboration aims to advance cancer research through the study of tumour mutations and new investigational therapies in prostate, pancreatic and potentially other cancers. "These are the first research collaborations AstraZeneca has established with Cambridge-based partners since announcing our intention to build a strategic research and development centre on the Cambridge Biomedical Campus," said Susan Galbraith, Head of AstraZeneca's Oncology Innovative Medicines Unit. "It is fitting that the focus of these collaborations is on delivering new medicines for cancer because our Cambridge facility will become AstraZeneca's largest centre for oncology research." The Full Research Report on AstraZeneca PLC - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/09cc_AZN]

Impax Laboratories Inc. Research Report

On July 15, 2013, Impax Laboratories Inc. (Impax) announced the commencement of shipment of authorized generic TRILIPIX (fenofibric acid) delayed release capsules, 45 mg and 135 mg, through Global Pharmaceuticals, Impax's generics division. Under the terms of a settlement agreement, Abbott Laboratories, now AbbVie Inc., and Fournier Laboratories Ireland Ltd. granted Impax the right to sell an authorized generic as early as July 15, 2013. The Full Research Report on Impax Laboratories Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/4c54_IPXL]

EDITOR NOTES:

  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
  5. For any urgent concerns or inquiries, please contact us at [email protected].
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

www.analystscorner.com

SOURCE Analysts' Corner

Suggested Articles

Sixteen years after it was approved, the FDA has ordered that heartburn drug Zantac and its generics be removed from the market.

In a non-randomized study in China, Avigan cleared virus after a median 4 days, significantly shorter than the 11 days observed for AbbVie's Kaletra.

Pfizer's 1.1-million-square-foot sterile injectables plant in Visakhapatnam has been criticized by the FDA for poor quality testing.